This site requires JavaScript and cookies to be enabled.

Eli and Laura’s ADHD story

Before his ADHD diagnosis and Qelbree treatment, Eli was struggling. Now he and his mom Laura see real progress in his ADHD management.

The individuals featured below are a real Qelbree patient and their family member; both are compensated ambassadors.

Qelbree helps Eli with his ADHD, at school and at home

Eli and Laura’s ADHD Story: Beyond Diagnosis

Hear from Eli and Laura on life after starting Qelbree.

As an elementary school student, Eli found himself struggling to keep up and became frustrated when he fell behind his classmates. Suspecting ADHD, Laura, his mom, and Eli sought treatment. He was diagnosed with ADHD by his healthcare provider and was prescribed Qelbree.

Four years later, Laura describes how Qelbree has helped Eli better manage his symptoms and slow down and process his thoughts and feelings rather than act out his frustrations and, in turn, allowing her to be less reactive.

Eli found help with Qelbree as a student who had challenging ADHD symptoms.

The copay card was helpful for our family this year, bringing the cost of Eli’s medication down to $20 a month.”*

Laura

Mother of son with ADHD

Paid spokesperson for Qelbree

See more ADHD stories

See the difference Qelbree is making in helping real people manage their ADHD.
Explore stories

Share your story

Share your experience of navigating ADHD with Qelbree.
Share your story

ADHD in children

Explore common ADHD symptoms that may affect children.
ADHD in children

Connect with the Qelbree community

Follow Qelbree on social media for updates.

Visit Facebook Visit Instagram Visit TikTok Visit Snapchat Visit our YouTube channel All about ADHD

*Terms and Conditions

This offer is good for most commercially insured and cash-paying patients purchasing Qelbree® and may not be used for any other product. Maximum benefits and quantity of capsules may apply. This offer is not valid for prescriptions purchased under Medicaid, Medicare, or other federal or state programs (such as medical assistance programs). Offer not valid where prohibited by law, taxed, or restricted. It is not transferable and may not be combined with any other offer. The amount of the rebate cannot exceed the patient’s actual out-of-pocket expenses. Offer must be presented along with a valid prescription for Qelbree at the time of purchase. By enrolling into this program you are consenting to the collection and use of certain personal information, including your phone number and/or email address and elements of pharmacy claim information. This information will be collected and used by service providers of Supernus Pharmaceuticals, Inc. (“Supernus”), in order to administer this program. This information is not provided to Supernus directly. If you do not consent, please do not enroll into the program. If you require additional assistance, please call 1-866-398-0833. Supernus reserves the right to rescind, revoke, or amend this offer without notice at any time.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE

INDICATION

Qelbree® (viloxazine extended-release capsules) is a prescription medicine used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment [read more] or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. [read more] Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Medication Guide, including Boxed Warning.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE

INDICATION

Qelbree® (viloxazine extended-release capsules) is a prescription medicine used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment [read more] or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. [read more] Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Medication Guide, including Boxed Warning.